Following a full submission
AWMSG advice |
|
| Status: Recommended with restrictions | |
This product is not currently marketed in the UK. Levodopa-carbidopa-entacapone (Lecigon®) is recommended as an option for restricted use within NHS Wales. Levodopa-carbidopa-entacapone (Lecigon®) is licensed for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results. Levodopa-carbidopa-entacapone (Lecigon®) is restricted within the licensed indication for patients who are not eligible for deep brain stimulation. Levodopa-carbidopa-entacapone (Lecigon®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|
Medicine details |
|
| Medicine name | levodopa/carbidopa/entacapone (Lecigon®) |
| Formulation | 20 mg/ml 5 mg/ml 20 mg/ml intestinal gel |
| Reference number | 4871 |
| Indication | Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results |
| Company | Britannia Pharmaceuticals |
| BNF chapter | Central nervous system |
| Submission type | Full |
| Status | Recommended with restrictions |
| Advice number | 0223 |
| NMG meeting date | 01/03/2023 |
| AWMSG meeting date | 19/04/2023 |
| Date of issue | 27/04/2023 |
| Commercial arrangement | WPAS |
| Further information This product is not currently marketed in the UK. |
|